CAD
Research type
Research Study
Full title
Colchicine And Dialysis patients; a feasibility study
IRAS ID
335421
Contact name
Michael Robson
Contact email
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
At present, colchicine is often avoided in patients receiving dialysis. Patients on haemodialysis take a number of medications already and have significant comorbidity. Therefore, it is possible that a higher proportion would have difficulty tolerating colchicine. These concerns mean that a large trial assessing the potential benefits of colchicine in this population cannot begin without further data on feasibility.
This feasibility study will establish whether low dose colchicine is tolerated and acceptable to dialysis patients and will help us to plan recruitment to future clinical trials. We will give colchicine to 100 dialysis patients. We will monitor them for side effects and see how many continue to take it for the planned period of 3 months. If feasibility is confirmed, there are then strong rationales for large clinical trials exploring the effect of colchicine on both mortality and vascular access outcomes in dialysis patients.
REC name
Wales REC 6
REC reference
24/WA/0277
Date of REC Opinion
4 Nov 2024
REC opinion
Further Information Favourable Opinion